Articles Vol. 67 No. Số CĐ12- Bệnh viện Ung bướu Nghệ An (2026) 14/08/2026

SECOND-LINE DOCETAXEL MONOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA AT NGHE AN ONCOLOGY HOSPITAL

Hoang Thi Xuan1,2, Hoang Thi Xuan1,2, Vo Thi Chung1,2, Nguyen Viet Binh1,2, Vuong Thi Thuong1,2, Nguyen Thi Giang1,2
1 Nghe An Oncology Hospital
2 Bệnh viện Ung Bướu Nghệ An
DOI: 10.52163/yhc.v67iCD12.6128
643 Views
0 Downloads
Keywords
Docetaxel, esophageal squamous cell carcinoma, second-line therapy.
Abstract

Objective: To evaluate the treatment outcomes of second-line Docetaxel monotherapy in patients with esophageal squamous cell carcinoma at Nghe An Oncology Hospital.

Subjects and methods: A retrospective descriptive study was conducted on 61 patients with esophageal squamous cell carcinoma who received second-line Docetaxel monotherapy between January 2023 and December 2025 at Nghe An Oncology Hospital.

Results: The mean age of the patients was 59.79 ± 6.7 years. The proportion of patients completing six cycles of chemotherapy was 45.9%. The disease control rate was 49.2%, with a partial response rate of 32.8%. Tumor T stage, overall disease stage, number of metastatic organs, and sites of metastasis were significantly associated with treatment response (p < 0.05). The most common hematologic toxicity was neutropenia, with grade 3-4 neutropenia occurring in 14.8% of patients; febrile neutropenia was observed in 8.2% of patients. Other adverse events were predominantly grade 1-2.

Conclusion: Second-line Docetaxel monotherapy demonstrated favorable efficacy and an acceptable safety profile in patients with esophageal squamous cell carcinoma who experienced disease progression following first-line treatment.

References
[1]
Kojima T, Shah M.A et al. Randomized phase III KEYNOTE-181 study of Pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol Off J Am Soc Clin Oncol, 2020, 38 (35): 4138-48. doi: 10.1200/JCO.20.01888. Google Scholar
[2]
Song Z et al. Second-line Docetaxel-based chemotherapy after failure of Fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma. Onco Targets Ther, 2014: 7: 1875-81. doi: 10.2147/OTT.S66525. Google Scholar
[3]
Albertsson M et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol, 2007, 24 (4): 407-12. doi: 10.1007/s12032-007-0028-6. Google Scholar
[4]
Ford H.E.R, Marshall A et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol, 2014, 15 (1): 78-86. doi: 10.1016/S1470-2045(13)70549-7. Google Scholar
[5]
Muro K, Hamaguchi T et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol, 2004, 15 (6): 955-9. doi: 10.1093/annonc/mdh231. Google Scholar
[6]
Nguyễn Việt Anh, Cao Thị Thanh, Phạm Văn Thắng. Kết quả điều trị phác đồ Docetaxel-Cisplatin trong ung thư biểu mô thực quản giai đoạn tái phát, di căn. Tạp chí Y học Việt Nam, 2025, 553 (3): 69-73. doi: 10.51298/vmj.v553i3.15439 Google Scholar
[7]
Ghazy H.F, El-Hadaad H.A et al. Metastatic esophageal carcinoma: prognostic factors and survival. J Gastrointest Cancer. 2022 Jun; 53 (2): 446-50. doi: 10.1007/s12029-021-00610-4. Google Scholar
[8]
Trần Thị Kim Anh, Trịnh Lê Huy. Kết quả điều trị phác đồ M-DCF trong ung thư biểu mô thực quản giai đoạn di căn tại Bệnh viện Đại học Y Hà Nội. Tạp chí Y học Việt Nam, 2022, 519 (1): 115-120. doi: 10.51298/vmj.v519i1.3529 Google Scholar
[9]
Nguyễn Thu Trang, Đỗ Anh Tú. Kết quả hóa trị phác đồ Paclitaxel và Carboplatin bước 1 trên người bệnh ung thư thực quản giai đoạn IV tại Bệnh viện K. Tạp chí Y học Việt Nam, 2024, 536 (2): 39-42. doi: 10.51298/vmj.v536i2.8871 Google Scholar